Peptide Medicine's Gray Market Is Closing. Here's What Comes Next.
The gray-market peptide ecosystem — BPC-157, TB-500 — is formalizing under regulatory pressure. What that shift means for biohackers who depend on it.
Tru Niagen at GNC and Sam's Club Signals NAD+ Has Left the Longevity Niche
The number one NAD+ supplement in the US is now in nearly 300 retail locations across 44 states. What the GNC and Sam's Club expansion says about where the longevity market is heading.
Wonderfeel: What a 4,235% Growth Rate Signals for the NAD+ Supplement Market
The NAD+ longevity brand ranked No. 1 biotech on the 2026 Inc. 5000. The growth rate reflects a consumer longevity market that's moving faster than most industry observers expected.
5 Perimenopause Supplements That Actually Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are under-dosed marketing. This evidence-graded breakdown identifies five options that hold up on clinical data, labeled doses, and standardized extracts.
5 Perimenopause Supplements That Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are underdosed and opaque. This evidence-graded breakdown applies clinical trial dosing standards to the current field — here are the five that survive scrutiny.
Peptides: Peter Attia's Framework for Separating Science from Marketing
Peter Attia's episode #403 gives biohackers a rigorous 5-question test for evaluating peptides — and most gray-market compounds fail at question one.
Healthy Aging: Why Exercise Is Non-Negotiable and Protein Is Supporting Cast
New research reframes the protein-first aging model. Exercise is the irreducible core of healthy aging — protein helps, but it doesn't replace what movement does at the cellular level.
Protein Restriction for Kidney Disease: What the Evidence Actually Shows
Peter Attia reviews the MDRD trial and Cochrane data: the default CKD advice to restrict protein lacks the evidence base it's been given — and the biggest trial showed higher long-term mortality in the restriction group.
Niagen's NR Study: A 2.5-Year Drop in Muscle Epigenetic Age
A new peer-reviewed analysis links NR supplementation to a 2.5-year reduction in muscle epigenetic age — though the funding company calls the data preliminary.
Timeline Wins $5.3M Judgment Against Fake Urolithin A Sellers
A federal court awarded Timeline $5.3M and permanent injunctions against 19 counterfeit urolithin A sellers — a case that signals the longevity supplement market is finally getting real enforcement.
The $10 Billion Probiotic Problem: What the Evidence Shows and What Works Instead
The probiotic market generates $10 billion per year despite evidence that most commercial supplements don't persist in the gut. Here's what the studies say—and five mechanistically stronger alternatives.
C15:0: The Saturated Fat That Longevity Researchers Are Rethinking
Pentadecanoic acid — an odd-chain saturated fatty acid — is showing geroprotective properties that challenge blanket warnings against saturated fat, with initial research from Navy dolphin aging studies.
Rapalogix: $20M to Bring Rapamycin Anti-Aging Science to Skincare
Rapalogix Health raised a $20M Series A to expand rapamycin-based skincare targeting TORC1 — the cellular pathway behind systemic longevity interventions, now applied topically.
Nuritas' AI-Discovered Peptides Are Now in Frozen Yogurt — and 31 Countries
Nuritas uses AI to discover functional peptides from plant proteins, then validates them through clinical research. At IFT FIRST 2026, PeptiStrong arrived in frozen yogurt format. What this means for functional nutrition.
Why Smart People Believe Bad Health Advice: The Cognitive Bias Map
Intelligence doesn't protect against health misinformation — it often amplifies it. Here's the framework for recognizing which cognitive traps are most likely to corrupt your health decision-making.
Elysium Creatine+: A Three-Ingredient Stack Targeting Strength, Recovery, and Longevity
Elysium Health's new Creatine+ combines creatine monohydrate with HMB and pomegranate-derived urolithin A precursors — a longevity-focused formulation co-developed with a Stanford longevity researcher.
Geroscience Is Rewriting the Logic of Disease Prevention
Thirty percent of centenarians escape major age-related disease entirely — not by treating conditions as they arrive, but by aging differently. Geroscience targets the shared biological mechanisms underlying multiple diseases simultaneously. Here's where the clinical evidence stands in 2026.
Sleep Pharmacology: Why Most Sleep Drugs Don't Deliver What You Think
Peter Attia's Episode 394 tackles which sleep medications actually work and which only sedate. The core insight — sedation is not sleep — reframes how to think about every drug in this category.
Peter Attia's Three-Question Framework for Cutting Through Supplement Noise
Peter Attia's AMA #85 framework for supplement evaluation: define the problem precisely, measure with a biomarker, and weigh risk against reward honestly.
Biohacking's Biggest Surprise: The Average Practitioner Is Over 65
The largest age group in biohacking is 65+, most practitioners spend under $500/month, and strength training beats peptide therapy 2:1.
Function Buys SuppCo: What Independent Supplement Testing Really Reveals
Function.health acquires SuppCo to add ISO-verified supplement testing to its 160-test biomarker platform. The backstory: roughly half of top-selling supplements fail their own label claims.
Niagen Plus: Why the NAD+ Market Just Went Injectable
Niagen Bioscience's $299 at-home injection kit delivers pharmaceutical-grade NR subcutaneously — bypassing gut metabolism. What the biohacking shift to injectables signals.
Peptides: Peter Attia Separates the Science From the Hype in AMA #83
BPC-157 has three small studies with no control groups. TB-500 and GHK-Cu have animal data only. Peter Attia's AMA #83 maps what the evidence actually shows — and why the regulatory picture is shifting fast.
Magnesium Forms: Why the Type You Take Changes Everything
80% of people are magnesium deficient, but most supplements use a form with 4% bioavailability. Here's which form works for sleep, cognition, and energy.
Mimio: The Fasting Mimetic With a Peer-Reviewed RCT Behind It
Mimio's randomized placebo-controlled trial in Nature Scientific Reports shows reduced LDL, fasting glucose, and oxidized LDL in 8 weeks — without dietary changes or actual fasting.
NR Sales Hit $129M: What Niagen Bioscience's 30% Growth Signals About the NAD+ Market
Niagen Bioscience reported $129.4M in 2025 revenue — up 30% — with net income more than doubling. The NAD+ precursor category is no longer a niche bet.